Dated: February 11, 1998.

Reginald F. Wells,

Acting Commissioner, Administration on Developmental Disabilities.

[FR Doc. 98–4115 Filed 2–18–98; 8:45 am]

BILLING CODE 4184–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Fiscal Year 1998 Discretionary Announcement for University-Head Start Partnerships Research Projects and Head Start Research Scholars; Availability of Funds and Request for Proposals

AGENCY: Administration on Children, Youth and Families, ACF, DHHS.

ACTION: Notice.

SUMMARY: The Administration for Children and Families, Administration on Children, Youth and Families announces the availability of funds for two Priority Areas; University-Head Start Partnerships (1.01) and Head Start Research Scholars (1.02) to support research activities in the areas of infant and toddler development within the cultural context, the promotion of mental health in Head Start and Early Head Start, or field-initiated research areas which will increase our knowledge of low-income children's development for the purpose of improving services or have significant policy implications.

DATES: The closing date for receipt of applications is 5:00 EST May 5, 1998.

ADDRESSES: Applications, including all necessary forms can be downloaded from the Head Start web site at www.acf.dhhs.gov/programs/hsb. The web site also contains a listing of all Head Start and Early Head Start programs.

Hard copies of the application may be obtained by writing, calling or sending an e-mail to the E-mail hsresearch@dakota-tech.com

FOR FURTHER INFORMATION CONTACT: Head Start Research Support Center at: 11320 Random Hills Road, Suite 105, Fairfax, Virginia 22030, Phone: (703) 218–2480.

SUPPLEMENTARY INFORMATION:

Priority Areas

Priority Area 1.01 University-Head Start Partnerships

Eligible Applicants: Universities and four-year colleges on behalf of a faculty member who holds a doctorate degree or equivalent in their respectivie field.

Project Duration: The announcement for priority area 1.01 is soliciting applications for project periods of three years with the first year as a planning year. However, requests for project periods of four or five years will be considered if the applicant can make a strong justification for the need for the longer project period in order to complete the research. It should be noted that the requests for longer project periods will be granted in only rare instances. Awards, on a competitive basis, will be for the first one-year planning budget period. Applications for continuation grants funded under these awards beyond the one-year budget period, but within the established project period, will be entertained in subsequent years on a non-competitive basis, subject to availability of funds, satisfactory progress of the grantee and a determination that continued funding would be in the best interest of the Government.

Federal Share of Project Costs: The maximum Federal share is $75,000 for the first 12-month budget period. The Federal share for subsequent years shall be approximately $150,000 per year for each year of the project period. The Federal share is inclusive of indirect costs.

Anticipated Number of Projects to be Funded: It is anticipated that 6–8 projects will be funded.

Priority Area 1.02 Head Start Research Scholars

Eligible Applicants: Institutions of higher education on behalf of qualified doctoral candidates who have completed their masters degree or equivalent and are enrolled in the sponsoring institution. To be eligible to administer the grant on behalf of the student, the institution must be fully accredited by one of the regional accrediting commissions recognized by the Department of Education and the Council on Post-Secondary Accreditation. In addition, the specific graduate student on whose behalf the application is made must be identified and any resultant grant award is not transferable to another student. Funds from this grant may not be used to make any payments to other students at the university.

Project Duration: The announcement for priority area 1.02 is soliciting applications for project periods up to two years. Awards, on a competitive basis, will be for a one-year budget period, although project periods may be for two years. It should be noted, that if the graduate student, on whose behalf the University is applying, expects to receive a doctorate by the end of the first one-year budget period, the applicant should request a one-year project period only. A second year budget-period will not be granted if the student has graduated by the end of the first year. Applications for continuation grants funded under these awards beyond the one-year budget period, but within the two-year project period, will be entertained in the subsequent year on a non-competitive basis, subject to availability of funds, satisfactory progress of the grantee and a determination that continued funding would be in the best interest of the Government.

Federal Share of Project Costs: The maximum Federal share is not to exceed $15,000 for the first 12-month budget period or a maximum of $30,000 for a 2-year project period.

Anticipated Number of Projects to be Funded: It is anticipated that 10 projects will be funded. No individual university will be funded for more than one candidate unless 10 applications from different institutions do not qualify for support.

Statutory Authority: The Head Start Act, as amended 42 U.S.C. 9801 *et seq.*

Dated: February 11, 1998.

James A. Harrell,

Deputy Commissioner, Administration on Children, Youth, and Families.

[FR Doc. 98–4113 Filed 2–18–98; 8:45 am]

BILLING CODE 4184–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Anti-Infective Drugs Advisory Committee Meeting; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Anti-Infective Drugs Advisory Committee meeting. This meeting was announced in the **Federal Register** of February 3, 1998 (63 FR 5562). The amendment is being made to reflect a change in the agenda for the February 19, 1998, meeting day. An additional indication for use in the treatment of infections caused by *Staphylococcus aureus* will also be discussed. There are no other changes. This amendment will be announced at the beginning of the open portion of the meeting.

FOR FURTHER INFORMATION CONTACT: Ermona B. McGoodwin or Danyiel A. D'Antonio, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12530.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of February 3, 1998 (63 FR 5562), FDA announced that a meeting of the Anti-Infective Drugs Advisory Committee would be held on February 19 and 20, 1998. This amendment is to provide an update to the information provided earlier pertaining to the February 19, 1998, meeting day. There are no changes for the February 20, 1998, meeting day. On page 5562, in the second column, the ''*Agenda*'' portion is amended to read as follows:

Agenda: On February 19, 1998, the committee will discuss new drug applications 50–747 and 50–748 quinupristin/dalfopristin (Synercid®, Rhone-Poulenc Rorer Pharmaceuticals, Inc.) for use in the treatment of vancomycin-resistant *Enterococcus faecium* (VREF) infections, complicated skin and skin structure infections, community-acquired pneumonia, hospital-acquired (nosocomial) pneumonia, and infections caused by *Staphylococcus aureus*.

Dated: February 11, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98–4078 Filed 2–18–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Blood Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Blood Products Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on March 19, 1998, 8 a.m. to 6 p.m., and March 20, 1998, 8 a.m. to 3:30 p.m.

Location: DoubleTree Hotel, Plaza I, II and III, 1750 Rockville Pike, Rockville, MD.

Contact Person: Linda A. Smallwood, Center for Biologics Evaluation and Research (HFM–350), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–3514, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 19516. Please call the Information Line for up-to-date information on this meeting.

Agenda: On March 19, 1998, the Committee will hear an informational summary of the emerging infections plan of action and discuss and provide recommendations on the issue of the FDA proposal on plasma inventory hold. The committee will also discuss the comparison of infectious disease marker rates in paid versus volunteer donors. On March 20, 1998, the Committee will discuss and make recommendations on the issue of classification of blood bank software and the relative safety of solvent detergent-treated pooled plasma and single-donor plasma, donor retested. The meeting will conclude with an informational presentation on the FDA proposal for donor deferrals related to xenotransplantation.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by March 9, 1998. Oral presentations from the public will be scheduled between approximately 10:30 a.m. and 11 a.m. and 4 p.m. and 5 p.m on March 19, 1998, and between approximately 9:30 a.m. and 10 a.m. and 1 p.m. and 1:30 p.m. on March 20, 1998. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before March 9, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C., app. 2).

Dated: February 11, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98–4075 Filed 2–18–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Oncologic Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Oncologic Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on March 19 and 20, 1998, from 8 a.m. to 5 p.m.

Location: Holiday Inn, Versailles Ballroom, 8120 Wisconsin Ave., Bethesda, MD.

Contact Person: Karen M. Templeton-Somers or Adele S. Seifried, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12542. Please call the Information Line for up-to-date information on this meeting.

Agenda: On March 19, 1998, the committee will discuss: (1) New drug application (NDA) supplement 20–509/S–005 Gemzar® (gemcitabine HCl), Eli Lilly and Co., indicated as a single agent or in combination with cisplatin for the first-line treatment of patients with locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer; and (2) NDA 20–896 Xeloda™ (capecitabine) tablets, Hoffman-La Roche Inc., indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of paclitaxel and an anthracycline-containing chemotherapy. On March 20, 1998, the committee will discuss: (1) NDA supplement 20–262/S–026 Taxol® (pacletaxel) injection, Bristol-Myers Squibb Pharmaceutical Research Institute, indicated as first-line therapy for the treatment of advanced carcinoma of the ovary; and (2) NDA supplement 20–262/S–024 Taxol® (pacletaxel) injection, Bristol-Myers Squibb Pharmaceutical Research Institute, indicated for the treatment of non-small cell lung cancer in patients who are not candidates for potentially curative and/or radiation therapy.